NMN and NR for Adults 65+: What Geriatric Patients Need to Know Before Starting NAD+ Precursors

Why NAD+ Decline Matters After 65

NAD+ is a cofactor required for hundreds of enzymatic reactions, including mitochondrial energy production, DNA repair through PARP enzymes, and sirtuin-mediated regulation of metabolic genes. Preclinical work has shown that falling NAD+ disrupts communication between the nucleus and mitochondria and produces a pseudohypoxic-like state in tissue, a mechanism described in mouse models by Gomes and colleagues [1]. Reviews of NAD+ metabolism describe NAMPT (nicotinamide phosphoribosyltransferase) as the rate-limiting enzyme in the pathway that recycles nicotinamide back into NAD+, and note that its activity is thought to decline with age in several tissues [2][3]. That decline is the biological rationale for why simply eating more niacin does not fully replace what is lost, and why NMN and NR are marketed as ways to bypass or support that salvage pathway.

The often-repeated claim that human skeletal muscle NAD+ falls by roughly half between age 40 and 70 circulates widely, but it should be treated as a figure to confirm against a primary human tissue study before it goes into a published page. The mechanistic evidence for age-related NAD+ decline is much stronger than the evidence for any single precise percentage in a general older-adult population.

NMN enters the NAD+ synthesis pathway downstream of NAMPT. NR enters at a slightly earlier step, through NRK kinases, and is converted to NMN inside cells before continuing on the same pathway. Both approaches have been shown to raise blood and, in some studies, tissue NAD+ in humans, including in some studies conducted in adults over 65.

What Has Actually Been Studied in Adults 65 and Older

Most of the widely cited NAD+ precursor trials were conducted in middle-aged or mixed-age adults, not specifically in a geriatric population. A smaller number of trials enrolled older adults directly, and those deserve the most weight when counseling a patient in this age group.

NMN in healthy older men. A randomized trial in healthy older men (mean age in the mid-60s) tested oral NMN at 250 mg daily over 12 weeks and reported an increase in whole-blood NAD+ along with changes in some measures of muscle function, without serious adverse events [4]. This is one of the few NMN trials conducted specifically in an older population, but it enrolled men only, which limits how confidently the result can be extended to older women.

NR in older individuals. A trial of acute (short-term) NR supplementation in old individuals reported improvements in markers of redox homeostasis and exercise performance [5]. Because dosing was acute rather than sustained over months, it speaks to short-term physiological effects rather than to what happens with long-term daily use.

NR in middle-aged and older adults combined. A chronic NR supplementation trial in a cohort that spanned middle-aged and older adults found the compound well tolerated and confirmed it raised NAD+ metabolome markers in blood over a period of weeks [6]. Because the cohort mixed middle-aged and older participants, results for the oldest patients within that range may differ from the group average.

NMN in postmenopausal women with prediabetes. A frequently cited NMN trial found that 250 mg daily improved skeletal muscle insulin sensitivity in postmenopausal women with prediabetes [7]. This is genuinely useful human efficacy data, but the population is specific: postmenopausal, prediabetic, and not necessarily representative of a general 65-plus population, male patients, or people without insulin resistance.

NMN safety data in a middle-aged cohort. A safety and tolerability study in healthy middle-aged adults is often cited for geriatric safety reassurance [8]. The population described in that trial is middle-aged rather than specifically geriatric, so its reassuring safety signal should be read as supportive rather than as direct geriatric-population evidence.

The pattern across this literature is consistent: NAD+ precursors reliably raise blood NAD+ in the populations tested, including in the older-adult studies, but the number of trials enrolling people specifically 65 and older, across both sexes, and including common geriatric comorbidities, is small. Precise effect sizes for blood pressure, muscle strength, or other outcomes attributed to specific trials should be checked against the original paper before being stated as a fixed number in patient-facing material, since several of those figures could not be confirmed against the source references available for this draft.

NMN vs. NR: What Distinguishes Them in Older Adults

There is no completed head-to-head trial comparing NMN and NR specifically in adults over 65. The choice between them currently comes down to route of metabolism, cost, and which population each has been tested in, rather than a documented efficacy advantage of one over the other.

Oral NR pharmacokinetics have been characterized in healthy volunteers, showing that NR is orally bioavailable and raises the blood NAD+ metabolome after single and repeated dosing [9][10]. NMN pharmacokinetics have likewise been studied in healthy and older cohorts, with blood NAD+ increases reported after weeks of daily dosing [4][7]. Both compounds converge on the same synthesis pathway once inside the cell, which is consistent with both raising NAD+ by a similar downstream mechanism even though they enter at different points.

At equivalent NAD+-raising doses, NR products are generally more expensive per month than NMN products in the US market. For patients on a fixed income, a common reality in geriatric care, that cost difference is a legitimate part of the discussion, independent of any efficacy claim.

Dosing Ranges Studied in Older Adults

Clinical trials in this area have generally used lower doses than some retail supplement marketing suggests, and geriatric pharmacology principles support starting low given reduced renal clearance, lower body water content, and age-related changes in hepatic first-pass metabolism.

NMN. Trials in older adults have most often used 250 mg once daily, typically taken with food [4][7]. Dose escalation toward 500 mg per day has been used in some studies, but the evidence base for going beyond 250 mg specifically in patients over 65 is thinner than the evidence at 250 mg. Patients with CKD stage 3 or higher (eGFR under 45 mL per minute per 1.73 m2) are a reasonable group to keep at the lower end of this range, since nicotinamide metabolites are cleared partly by the kidney and reduced renal function could plausibly allow them to accumulate, based on general NAD+ metabolism and clearance data rather than a dedicated renal-impairment trial [11].

NR. Trials have most often used doses in the 500 to 1,000 mg per day range, sometimes split into two doses to reduce nausea [6][9]. As with NMN, a lower starting dose with a slower taper upward is a reasonable, conservative approach in a geriatric patient rather than a formally validated protocol specific to that age group.

Preclinical circadian biology work suggests NAD+ synthesis may be more active during the daytime active phase, which is the basis for a common recommendation to dose NAD+ precursors in the morning rather than the evening [12]. This recommendation is extrapolated from mechanistic and animal data rather than from a human trial that directly compared morning and evening dosing, and it should be presented to patients as a reasonable precaution rather than an established clinical requirement.

Drug Interactions to Review Before Starting

Older adults commonly take several prescription medications at once, which makes a structured interaction review a necessary step before starting NMN or NR, not an optional one.

Warfarin and Other Anticoagulants

High-dose pharmacological niacin, a downstream metabolite pathway shared with NMN and NR, has a documented ability to potentiate warfarin's anticoagulant effect at the doses used for lipid management [13]. The doses of nicotinamide generated from typical NMN or NR supplementation are far lower than pharmacological niacin doses, and no trial has specifically measured INR changes with NMN or NR. Given the shared metabolic pathway, checking INR after starting or changing dose in a patient on warfarin is a reasonable, low-cost precaution rather than a formally established requirement. Patients on direct oral anticoagulants should also be informed, since the interaction has not been studied in that group either.

PARP Inhibitors and Chemotherapy

PARP inhibitors (olaparib, rucaparib, niraparib, and related drugs) work partly by depleting NAD+ in cancer cells, and there is a credible mechanistic case that raising NAD+ with a supplement could blunt that effect [14]. This interaction has not been studied directly in humans taking both a PARP inhibitor and an NAD+ precursor. Given the mechanism, a patient on active PARP inhibitor therapy should not start NMN or NR without checking with their oncology team first, as a matter of site judgment rather than a documented society guideline.

Metformin

Metformin inhibits mitochondrial complex I, which raises the NADH-to-NAD+ ratio and lowers free NAD+, so there is a plausible mechanistic reason NAD+ precursors and metformin could interact. Robust published human data testing this specific combination in older adults were not identified for this draft. Clinicians should treat this as an open question rather than a settled reassurance, and glucose monitoring around the time of starting either drug is a reasonable precaution.

Safety Signal in the Available Trials

The safety data from human trials of NMN and NR are reassuring overall, but nearly all of the foundational trials excluded people with significant comorbidity, and geriatric patients frequently have exactly the comorbidities those trials excluded.

Across the available studies, the most commonly reported adverse effects have been mild and gastrointestinal, including nausea, loose stools, and abdominal discomfort, generally described as transient and not requiring discontinuation [8][9]. Serious adverse events attributable to NMN or NR have been uncommon in the published trials, though the total number of patient-years studied remains small, and exact incidence figures vary by study and population, so a specific percentage should be pulled from the primary paper rather than repeated as a fixed number across a general audience.

The Methylation Question

NMN and NR are eventually broken down to nicotinamide, which is methylated by NNMT (nicotinamide-N-methyltransferase) for excretion. High-dose supplementation could theoretically consume methyl groups and affect the methionine cycle, a concern grounded in general sirtuin and NAD+ metabolism biology [3][15]. This is a theoretical concern at doses above roughly 1,000 mg per day rather than one with an established clinical incidence. Checking plasma homocysteine at baseline and around 12 weeks is a reasonable precaution in patients with a known MTHFR variant, elevated homocysteine, folate deficiency, or a dose above 500 mg per day.

Population-Specific Evidence and Transferability Map

Because so few trials enroll people specifically 65 and older, it helps to be explicit about which claims rest on direct evidence in this age group, which are extrapolated from a related population, which come only from mechanistic or animal data, and which require specialist input before proceeding. This map is meant to guide a conversation with the patient and their other clinicians, not to substitute for that conversation.

Outcome to track once a geriatric patient starts either compound: fasting glucose and metabolic panel trend, any new bleeding or bruising in anticoagulated patients, gastrointestinal tolerance, and whether the original goal of use (fatigue, metabolic support, or another stated goal) has actually moved, since none of the current trials confirm a hard clinical endpoint that can be assumed in advance.

Monitoring Schedule for Geriatric Patients Starting NMN or NR

A structured monitoring plan is a matter of site judgment based on general geriatric pharmacology principles and the safety data above, not a protocol validated in its own trial.

Baseline (before first dose):

• Fasting glucose and HbA1c
• Comprehensive metabolic panel (liver enzymes and renal function)
• Complete blood count
• Plasma homocysteine (if dosing above 500 mg per day or a known MTHFR variant)
• INR if on warfarin

Around week 4:

• Fasting glucose
• INR (warfarin patients only)
• Brief symptom review for gastrointestinal complaints, sleep changes, or palpitations

Around week 12:

• Comprehensive metabolic panel
• Fasting glucose and HbA1c
• Plasma homocysteine, if obtained at baseline
• Patient-reported outcomes tied to the original goal of use: fatigue, physical performance, sleep quality

Annually, if continued:

• Full metabolic panel and CBC
• Re-review of concurrent medications for new interactions

Care Transitions: What to Document

When a patient already taking NMN or NR moves between providers or care settings, whether from a hospital to outpatient follow-up or from a general medicine provider to a geriatric specialist, supplement use is easy to lose in the handoff. Studies of older adults' medication and supplement use over time have documented substantial concurrent use of prescription drugs and supplements together, which raises the chance of an unreviewed interaction if the supplement is not carried forward in the record [16]. A transition summary for a patient on NMN or NR should include:

• The specific product, dose, and frequency (NMN 250 mg daily and NR 500 mg twice daily are meaningfully different protocols)
• Duration of use and any dose changes
• Results of any monitoring labs obtained during supplementation
• Known drug interaction concerns and how they were managed
• Whether oncology, nephrology, or another specialist has been consulted

Aligning on the Goal of Use

The stated goal of NMN or NR use, whether it is general metabolic support, addressing a specific symptom, or a broader interest in healthy aging, should be documented and revisited at each transition point. A patient who started NMN for fatigue at 67 may have a different risk-benefit picture at 75 after developing CKD stage 3 or starting new medications. The current American Geriatrics Society Beers Criteria do not list NMN or NR as a potentially inappropriate medication, but they also do not endorse them, which leaves clinician judgment as the primary guide in this population [17].

Current Regulatory and Evidence Status

The FDA has taken an enforcement discretion position that has allowed NMN to remain available as a dietary supplement in the US even while questions about its regulatory classification are unresolved [18]. In practice, this means NMN and NR are legal to purchase and use, but neither is FDA-approved for any medical indication, and neither has been evaluated by the FDA for safety and efficacy the way an approved drug would be.

No major medical society had, as of this writing, issued a clinical practice guideline specifically endorsing routine NAD+ precursor supplementation in older adults. The available human evidence establishes that both compounds reliably raise blood NAD+, including in some studies conducted in older adults, but confirming that a sustained NAD+ increase changes a hard clinical outcome such as falls, frailty progression, or mortality would require a larger and longer trial than any completed to date. Dr. Charles Brenner, whose research on NR pharmacology is part of the foundational literature in this area, has written publicly about this same gap between reliably raising NAD+ and proving that the increase changes long-term health outcomes [19]. The precise wording of any quotation attributed to him should be checked against the source article before publication rather than reproduced from this draft.

Practical Summary

Adults 65 and older who are interested in NMN or NR should get a structured pre-initiation review: baseline labs, a documented drug interaction check, and a clear statement of what outcome they and their clinician are hoping to see. For most older adults without significant renal or hepatic impairment, NMN 250 mg once daily with food is consistent with the doses used in the older-adult trials available. For patients with a strong preference for NR, 500 mg per day split into two doses is consistent with the trial data reviewed here. Follow-up labs around 12 weeks help confirm tolerability and track glucose and hepatic trends. Patients on warfarin should have an INR check after starting or changing dose. Patients on active PARP inhibitor therapy should not start NMN or NR without oncology input first.

The evidence supports NAD+ precursor supplementation as a generally low-risk intervention in the specific populations that have actually been studied. It does not yet support a claim that NMN or NR changes a hard clinical outcome in a general geriatric population, and that distinction should stay clear in any conversation with a patient.